Low does fampridine ineffective
13 August 2012
A study of a 5mg/twice daily dose of fampridine found no improvement in walking speed compared to placebo. The good news for Acorda, who make the drug, whose patent for the 10mg dose runs until 2027. The bad news is that in the current trial the 10mg dose also missed the primary endpoint, though did show improvements in secondary measures.
Items in MS in the Media link to recent news stories that may be of interest to people in the UK.
The MS Trust has not written the original items and does not endorse their content nor any claims made in them.
Click on the link beneath the item to be taken to the original story.